This article is more than 5 years old. Information may no longer be current.
ONO-9054 lowers IOP in early primary OAG, OHT
Click Here to Manage Email Alerts
Researchers reported lower intraocular pressure in subjects with early primary open-angle glaucoma or ocular hypertension following single and multiple day dosing with topical administration of ONO-9054, according to a study in the Journal of Glaucoma.
The phase 1, single-center, randomized, placebo-controlled, double-masked, dose-escalation study included subjects with ocular hypertension or primary open-angle glaucoma: nine patients were randomized to ONO-9054 3 µg/mL, 10 µg/mL, 20 µg/mL and 30 µg/mL, and 12 patients were randomized to placebo.
Patients received a single drop to each eye at about 7 a.m. for the single dosage. After a 4-day period with no treatment, subjects were dosed once daily for 14 consecutive days.
For single dosing, IOP decreased from 22.9 ± 4.0 mm Hg to 15.9 ± 2.3 mm Hg and at peak effect 9 hours post-dosage, the reduction in placebo-treated subjects was from 22.3 ± 2.4 mm Hg to 21.5 ± 3.3 mm Hg.
In multiple day dosing, the greatest IOP reduction was found 1 hour post-dosage on day 18, from 23.3 ± 0.6 mmHg to 15.1 ± 2.4 mmHg, according to the study.
The researchers found that single doses of ONO-9054 resulted in reductions in IOP across all treatment groups that were proportionate with dose concentration.
“The sustained reduction of IOP in the absence of continued dosing in subjects receiving ONO-9054 10 µg/mL and 30 µg/mL was consistent with the requirements for once-daily administration,” the researchers wrote. – by Abigail Sutton
Disclosure: Harris was a paid consultant to Ono Pharma. Please see the full study for all remaining authors’ financial disclosures.
Perspective
Back to Top
Scott Anthony, OD, FAAO
It has been almost 14 years since a novel drug-class of topical glaucoma medications has hit the market. Although we currently have different options within the prostaglandin analog drug-class, they all act upon the same prostaglandin receptor and offer similar efficacy. Today, we are on the brink of inheriting new drug-classes of glaucoma medications that will target the main facilitator of aqueous outflow, that being the trabecular meshwork.
Although ONO-9054 builds upon the mechanisms of traditional prostaglandin analogs, it aims to target new prostaglandin receptors for a potentially more powerful effect than what is currently available. Altogether, it will be exciting to offer patients new, possibly more effective topical glaucoma medications than ever seen before.
The revolution for pharmaceutical developments in glaucoma has begun. Now we need to find a way to tackle the issue of compliance, which continues to dog even the best of treatments available.
Click Here to Manage Email Alerts